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Purpose: Liver tumors are challenging to visualize on cone beam computed tomography (CBCT)
without intravenous (IV) contrast. Image guidance for liver cancer stereotactic body ablative
radiation therapy (SABR) could be improved with the direct visualization of hepatic tumors and
vasculature. This study investigated the feasibility of the use of IV contrast-enhanced CBCT
(IV-CBCT) as a means to improve liver target visualization.
Methods and Materials: Patients on a liver SABR protocol underwent IV-CBCT before 1 or more
treatment fractions in addition to a noncontrast CBCT. Image acquisition was initiated 0 to 30
seconds following injection and acquired over 60 to 120 seconds. “Stop and go” exhale breath-hold
CBCT scans were used whenever feasible. Changes in mean CT number in regions of interest
within visible vasculature, tumor, and adjacent liver were quantiﬁed between CBCT and IV-CBCT.
Results: Twelve pairs of contrast and noncontrast CBCTs were obtained in 7 patients. Intravenous-
CBCT improved hepatic tumor visibility in breath-hold scans only for 3 patients (2 metastases, 1
hepatocellular carcinoma). Visible tumors ranged in volume from 124 to 564 mL. Small tumors in
free-breathing patients did not show enhancement on IVCBT.
Conclusions: Intravenous-CBCT may enhance the visibility of hepatic vessels and tumor in CBCT
scans obtained during breath hold. Optimization of IV contrast timing and reduction of artifacts to
improve tumor visualization warrant further investigation.Sources of support: This work is funded in part by the National Cancer Institute of Canada and the Canadian Cancer Society.
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Stereotactic body radiation therapy (SABR) relies on
accurate patient positioning and delivery of radiation to
ensure the target receives the intended dose, while mini-
mizing the dose to the surrounding normal tissues. Kilo-
voltage (kV) cone beam computed tomography (CBCT)
allows volumetric images to be acquired with the patient in
the treatment position at the treatment unit immediately
before radiation therapy (RT) delivery.1 Despite respiratory
liver motion, which can range from 5 to 50 mm in the
craniocaudal dimension,2 kV CBCT for image guided RT
(IGRT) of liver cancers is feasible.3 However, because
liver tumors are generally not visible without intravenous
(IV) contrast, surrogates such as radiopaque markers,4 prior
transarterial chemoembolization sites, or the liver itself, are
generally used for IGRT. Because changes in the size,
shape, and position of tumors (and normal tissues)
have been noted during treatment of liver cancers,3 and
motion and/or deformations seen in the liver may not be
representative of the tumor,5 there is uncertainty in use of
standard surrogates for IGRT.
Direct visualization of the liver tumor itself on CBCT
would allow tumor-to-tumor volumetric image guidance,
which should improve accuracy of liver SABR. Because
most liver tumors have similar CT attenuation to normal
liver parenchyma, IV contrast is given to enhance
visualization of hepatic tumors.6 The relative differences
in inﬂux, washout, retention, and/or accumulation of IV
contrast between tumor and normal tissues during
dynamic contrast-enhanced (DCE) CT imaging is useful
for liver tumor detection and characterization. During
DCE CT, hypovascular tumors (eg, colorectal liver
metastases), appear iso-dense during the arterial phase
(approximately 30 seconds after injection onset) and
hypodense during the portal-venous phase (approxi-
mately 60 seconds after injection onset). Hepatocellular
carcinomas (HCCs) demonstrate enhancement during
the arterial phase and washout (less intensity compared
with the adjacent liver) in the venous and delayed
phases (approximately 180 seconds after injection
onset). In light of these imaging principles, IV-CBCT
may enhance the visibility of intrahepatic tumors and
vessels with a view to improved image-guided stereo-
tactic body RT. This manuscript describes our initial
experience with the use of multifraction IV-CBCT for
liver SABR.Methods and Materials
Patients and eligibility
All patients provided informed consent for this local
research ethics boardeapproved protocol that investigated
IV contrast during research CBCT acquisition. Eligible
patients were 18 years of age or older, had Child-Pugh
class A liver function, Karnofsky performance status
greater than 60, normal creatinine (<109 mmol/L), and
were planned to be treated with SABR. Ineligibility
criteria included history of IV contrast allergy or reaction,
known renal disease, or diabetes.
Patients were treated either in exhale breath-hold
(BH) using the Active Breathing Control (ABC) device
(Elekta, Crawley, UK), or free-breathing (FB) with or
without abdominal compression using an in-house
developed device described elsewhere.7 Individualized
motion management was based on liver tumor motion
determined at simulation using kV ﬂuoroscopy, respi-
ratory sorted (4-dimensional [4D]) CT and cine MR
imaging. SABR was delivered in 6 fractions as previ-
ously described.8
CBCT
Cone beam CT scans were initially acquired using an
Elekta Synergy Research Platform (Elekta), composed of
a conventional x-ray tube and ﬂat panel detector (RID
1640; PerkinElmer, Wiesbaden, Germany), that uses a
Kodak Fast Lanex scintillator (Gd2O2S:Tb) of thickness
133 mg/cm2 mounted on the linear accelerator (Eastman
Kodak, Rochester, NY). The central axis of the kV beam
is perpendicular to the treatment megavoltage beam,
sharing the same center of rotation. Following the ﬁrst
5 IV CBCT scans, a commercially available linear
accelerator equipped with kV CBCT (Synergy, Elekta
Oncology Systems) was used. Scans acquired on the
research platform used 120 kVp, approximately 1289
mAs (total), and 3.3 or 5.5 frames per second; those
acquired on the Elekta Synergy system used 120 kVp,
approximately 1008 mAs (total), and 650 projections per
360 rotation. On both systems, in-house modiﬁcations
enabling the interruption of the CBCT acquisition by the
radiation therapist was used to facilitate the acquisition of
exhale BH only images in patients treated with ABC
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and go” CBCT).3 Free-breathing scans were acquired in 1
continuous acquisition. A maximum of 2 IV-CBCTs were
planned per patient, most commonly acquired at fractions
2 and 5. All images were acquired with the patient in the
treatment position immediately before or following radi-
ation therapy. IV access was gained before each IV-
CBCT and following a 10-mL test dose of IV contrast
(Visipaque; Amersham Health, Princeton, NJ), contrast
was administered at rate 3 to 5 mL/second, 2 mL/kg to a
maximum of 200 mL. Cone beam imaging was initiated
0 to 30 seconds following contrast injection and acquired
over 60 to 120 seconds. Noncontrast CBCTs were ac-
quired daily, with the patient in the treatment position,
either before the IV-CBCT or following completion of
radiation delivery.Data analysis
The IV-CBCT images were reconstructed and analyzed
using the Pinnacle v7.6b (Philips Medical, Madison, WI)
treatment planning system (TPS), by a radiation oncologist
with experience in both SABR liver treatment planning and
CBCT evaluation. A liver-to-liver manual fusion with
noncontrast CBCT scans from the same fraction and the
planning CT was performed to ensure the tumor and vessel
location was known in the CBCT scans, whether or not
there was enhancement. Regions of interest (ROI) in tumor
or vessel and normal surrounding liver were contoured on
the IV-CBCT and corresponding noncontrast CBCT. Re-
gions of interest were approximately 1 cm in diameter and
chosen in as homogeneous regions as possible, not over-
lapping edges of tumor or vessels. The CT numbers
(minimum, maximum, mean, and standard deviation)
within the ROIs were determined using the TPS’s
CT number, which is automatically generated for anyTable 1 Patient characteristics
IV CBCT Patient no. Age Sex Diseas
1
2
1 53 F Metas
3 2 61 M Metas
4
5
3 74 F Metas
6 4 75 M Metas
7
8
5 55 M Metas
9
10
6 74 M Metas
11
12
7 61 M Hepat
CBCT, cone beam computed tomography; F, female; GTV, gross tumor vol
a For patients with multiple GTVs, this is the sum total of all visible on
largest nonvascular thrombosis GTV was evaluated.segmented ROIs. The absolute difference in mean CT
numbers, between tumor/vessel and surrounding normal
liver, was compared between the IV-CBCT and non-
contrast CBCT and is represented by the formula adapted
from Nung et al9 (as presented in Siewerdsen et al10):
Absolute difference Z CTT  CTB. Where CTT is the
mean CT number tumor or vessel and CTB is the mean CT
number surrounding normal liver ROI, and SD is the
standard deviation of the CT numbers within the ROI. The
contrast-to-noise ratio (CNR) is the ability of an imaging
modality to distinguish between various contrasts and the
inherent noise within an image (eg, from imaging hardware
or tissue). The CNR is represented by the formula:
CNRZ
jCTT CTBj
sBResults
Patient characteristics and IV CBCT details
Between July 2006 and May 2007, 7 patients con-
sented to this protocol. Five patients had liver metastases
(4 colorectal, 1 melanoma), 1 had metastatic chol-
angiocarcinoma, and 1 had HCC (Table 1).
In total, 12 IV-CBCT and routine noncontrast CBCT
pairs were acquired. Some patients (nZ 2) were not able
to have a second IV-CBCT because of logistical reasons.
Images were acquired in ABC BH for 3 patients on both
occasions, FB on both occasions in 2 patients, FB with
abdominal compression on 1 occasion for a single patient,
and FB and voluntary BH on 1 occasion each for the ﬁnal
patient (Table 2). All patients received their total planned
contrast volume as per protocol. Cone beam CT scanse Total GTV
volume (mL)a
No. of
GTVs
tatic colorectal cancer 458.3 2
tatic colorectal cancer 123.9 1
tatic cholangiocarcinoma 10.5 3
tatic melanoma 62.7 3
tatic colorectal cancer 7.4 1
tatic colorectal cancer 66.3 1
ocellular carcinoma 563.7 2
ume; IV, intravenous; M, male.
contrast-enhanced planning CT. For the purposes of the IV-CBCT the
Table 2 Per-patient BH and FB IV-CBCT details
IV
CBCT
Patient
ID
Imaging system/
scan type
Contrast
volume (mL)
Respiratory
management
FB
amplitude
(cm)
Injection
time
Total
time (s)
Acquisition
time (s)
No.
BH
Tumor
visible?
Vessel
visible?
Per-patient BH IV-CBCT
1 1 RP/FS 120 BH 24 127 58 4 No Yes
2 RP/FS 120 BH 0 155 58 5 Yes Yes
4 3 RP/FS 120 BH 0 108 75 4 Yes Yes
5 RP/FS 120 BH 0 99 75 4 Yes Yes
8a 5 ES/HS 170 BH 0 263 101 6 No No
11 7 ES/HS 140 BH 0.9 8 117 60 4 Yes Yes
12 ES/HS 140 BH 9 118 60 4 Yes Yes
Per-patient FB IV-CBCT
3 2 RP/FS 135 FB 0.3 0 60 60 No No
6 4 ES/HS 150 COMP 0.8 0 90 60 No No
7 5 ES/HS 170 FB 2.0 0 117 117 No No
9 6 ES/HS 100 FB 3.0 9 129 120 No No
10 ES/HS 100 FB 10 130 120 No No
BH, breath hold; CBCT, cone bean computed tomography; COMP, abdominal compression; ES, Elektra Synergy CBCT; FB, free breathing; FS, full
scan (360 rotation); HS, half scan (200 rotation); IV, intravenous; RP, research platform.
a This patient is normally treated in FB and therefore had not received any BH training.
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(nZ 4), 386 (nZ 6), or 167 (nZ 2) projections. Table 2
summarizes patient and imaging characteristics.
Breath-hold patients had stop and go CBCT scans, in
which images were acquired only during repeat exhale
BHs, with short interruptions of the CBCT between
BHs. For the 7 BH IV-CBCTs, 5 were obtained with 4
repeat BHs (range, 4-6) per scan, with BH durations
ranging from 8 to 20 seconds (Table 2). One patient
(patient 5, scan 2) had difﬁculty with BH, and, because
prolonged interruptions, the total scanning time was 263
seconds. There were no complications from the IV
contrast.
The reproducibility of the liver and tumor position in
exhale BH and FB has been validated by this group previ-
ously,3,7,8,11-16 and as such is not the subject of the current
work.
Qualitative image analysis
The IV-CBCT scans were initially assessed visually by
an expert user (R.V.T.) in the Pinnacle TPS. Tumor was
visible in 5 of 7 (71%) BH IV-CBCT scans and vasculature
on 6 of 7 (86%) BH IV-CBCT scans. Tumor or vasculature
was enhanced in 42% and 50% of the BH IV-CBCT scans,
respectively. Figure 1 is a representative image of tumor
and vasculature enhancement in BH IV-CBCT.
CNR changes between tumor or vasculature and the
liver were only calculated in patients in which changes
were visualized. Details of the tumor/vasculature visual-
ization are summarized in Table 2. Although image 8 was
attempted as a “stop and go” exhale BH scan, this was in
a patient requiring long interruptions between image
acquisition in preparation for each subsequent BH. Inaddition to liver tumor and hepatic vasculature, IV-CBCT
showed considerable enhancement of kidney architecture
(which could prove useful in kidney SABR, Fig 2).
Quantitative image analysis
Hepatic vasculature was visible with relative contrast
enhancement in 6 BH IV-CBCT scans (3 patients, 2
metastases; 1 HCC). Contrast-to-noise ratio was calcu-
lated for all tumors and vessels visible by eye with a mean
(range) of 4.85 (1.49-9.61) and 1.75 (0.22-3.52), respec-
tively. The mean absolute difference in CT number
between vessel and liver for IV-CBCT and noncontrast
CBCT was 2.6% and 1.3%, respectively (P < .05).
Decreased tumor attenuation relative to the liver was
seen in 5 BH IV-CBCT scans (3 patients, 2 metastases; 1
HCC). In the IV-CBCT scans demonstrating tumor
enhancement, there was no delay from the start of contrast
injection to the start of image acquisition; all images were
acquired in the half-scan (200 rotation) format on the
research platform imager and contrast was injected at a
rate of 3 mL/second. The parameters for the scans on
which vasculature alone was visualized were more vari-
able (Table 2).
Discussion
In contrast to the early reports on respiratory correlated
IV contrast-enhanced CT in the liver17 and pancreas,18 this
is the ﬁrst multipatient report on the feasibility of IV-CBCT
for liver tumor visualization during SABR. Rodal et al
reported a case study of a dog with a maxillary tumor that
underwent 5 CBCT scans before and after administration
Figure 1 Intravenous cone bean computed tomography (IV-CBCT) images demonstrating tumor enhancement in patient 1. (A) Axial
CT slices comparing noncontrast CBCT (left) with simulation CT (middle) and IV-CBCT (right) from a single fraction. Arrows indicate
gross tumor volume (top) and gross tumor volume contour (black) from planning CT shown on bottom. Note the artifact from clips in
the CBCTs. (B) Sagittal CBCT slices with (left) and without (right) IV contrast demonstrating tumor visibility with contrast.
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onstrates a more clearly discriminated tumor than does non
contrast CBCT scan.19 Improved target visualization in RT
patients should improve accuracy of radiation delivery, by
using the tumor for image guidance, instead of a surrogate.
This is particularly beneﬁcial in liver SABR, in which the
tumor is not usually visible without IV contrast and sur-
rogates for the tumor (eg, whole liver, a portion of the liver,
inserted ﬁducial markers) are routinely used for IGRT and
treatment is delivered on only a few fractions. Several
authors20,21 have reported on the successful use of surro-
gates such as ﬁducial markers; these are still surrogates andnot the actual tumor. Should the actual visualization of the
target be feasible on a day-to-day basis, this could poten-
tially lead to more accurate tumor targeting. In the wake of
adaptive RT, actual target visualization may prove more
useful than the use of surrogates to modify treatments. In
addition, ﬁducial marker implantation may not be suitable
for all patients or, in some smaller centers, may require a
delay because of availability of specialist staff to perform
the implantation. As such, should IV-CBCT be available,
this could prove an alternate option for patients undergoing
short-course SABR. Intravenous-CBCT has proven useful
in several non-RT applications such as neurovascular stent
Figure 2 Intravenous cone bean computed tomography (IV-CBCT) images demonstrating normal tissue. (A) Coronal views of
IV-CBCT demonstrating hepatic vasculature (patient 3). (B) Kidney architecture with (left) and without (right) IV contrast (patient 1).
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tography,23 abdominal interventional procedures such as
angiography,24 and intra-arterial cranial chemotherapy.25 In
attempts to optimize tumor/vasculature visualization on
IV-CBCT, the procedure was modiﬁed over the course of
the study; thus, it is not surprising that there was variable
visualization of liver tumors and vasculature because the
timing of contrast administration and scan acquisition is
critical for target visualization on a helical contrast-
enhanced CT.6 Because all CBCT acquisitions were
acquired over 1 to 2 minutes, the contrast had time to
“wash-in” and “wash-out” of the tumor and vessels. If this
dynamic process could be quantiﬁed, there is the potential
for IV-CBCT to be used to measure perfusion, which is the
focus of ongoing research.26
Most patients in this study had metastatic liver dis-
ease, which tends to be hypovascular and enhances bestduring the portal venous and delayed phases of con-
ventional DCE CT, approximately 60 seconds
following onset of injection. In the work presented
here, all patients demonstrating tumor enhancement had
metastatic liver cancers and a mean acquisition time of
65.6 seconds, meaning the scans were complete
approximately in time with the venous uptake, avoiding
washout. For the 2 metastatic BH IV-CBCT scans not
demonstrating tumor enhancement, the acquisition
times were >80 seconds, likely too late to capture the
venous phase, but not late enough to demonstrate
delayed enhancement (which would only be useful for
primary liver cancers). However, further investigations
are required to draw ﬁrm conclusions. Because of the
length of time required for an IV-CBCT acquisition, it
is likely that tumor enhancement will vary over time,
with more predicted stability in the venous phase of
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(for primary liver cancers). It is possible that better
visualization of the tumors would have occurred if
the image quality was improved and/or with longer
imaging over the delayed phases. It is hypothesized
that, because of the time required for image acquisition,
this application may be better suited to late enhancing
tumors (eg, metastases) and/or tumors with sustained
washout (eg, HCC). Furthermore, it is not unexpected
that tumors were best seen on BH scans versus FB
scans, and it is expected that with more modern CBCT
(commercially available stop and go and 4D CBCT),
the chances of IV contrast leading to tumor or vascu-
lature visualization would be increased. The effects of
IV contrast on megavoltage photon dosimetry have
been studied by others,27-29 who have determined the
effects to be clinically insigniﬁcant. Because of the
majority of the IV contrast would be washed out at the
completion of the CBCT, it is unlikely that there would
be a clinically signiﬁcant effect of IV contrast on
delivered doses.
As an alternative to IV-CBCT, which leads to transient
target enhancement, there is motivation for a contrast
agent that may demonstrate sustained enhancement over
many radiation fractions. Nakagawa et al30 reported on
the injection of 3.5 mL lipiodol for this purpose in 2
patients (1 with brain metastases and 1 with HCC). When
motion reduction/elimination is not feasible, alternate
methods for improving online imaging should be used,
such as respiratory correlated CBCT, described by Sonke
et al.31 At the time of this analysis, real-time respiratory
correlated CBCT was not available. Retrospective respi-
ratory correlation of noncontrast-enhanced CBCT scans
has been used32 and further optimization of respiratory
correlated CBCT to eliminate artifacts in FB and
compression patients may improve the potential for IV
tumor localization for non-BH liver cancer SABR.
Although IV contrast can improve target and vessel
visualization in BH liver SABR, the routine use of IV
contrast over traditional RT courses may be associated
with added risk, and this approach is only recommended
for single or hypofractionated treatment schedules.
Alternative (more complex and expensive) strategies for
direct tumor visualization, such as magnetic resonance
integrated treatment units, are being investigated and may
improve accuracy of direct tumor localization in these
patients.33Conclusion
Intravenous contrast can enhance visualization of liver
vasculature and tumors in BH CBCT, but not in FB
CBCT, for the CBCT techniques investigated. Intrave-
nous CBCT has the potential to improve direct tumor
targeting during liver IGRT.Acknowledgments
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